Global Literature Review
Maintain compliance and enhance safety oversight with expert-driven literature evaluation and reporting.
Literature Search
The review of worldwide scientific literature is an essential part of the ongoing safety surveillance of medicinal products, regardless of commercial status. To ensure compliance with regulatory legislation worldwide, it is essential that global and local literature screening, where applicable, is regularly conducted to identify reportable ICSRs and safety relevant information.
Our experienced team at ProPharma can support you or assume full responsibility for these activities to ensure your PV program adheres to the global regulatory requirements.
In addition, our services are cost-effective, and we are able to conduct global literature surveillance of large bibliographical databases including Medline® via the Biologit platform.
We have extensive experience in developing robust search strategies for our clients and providing results from these searches according to an agreed upon periodicity. We can perform the review and assessment of identified literature articles and ensure the efficient and auditable documentation of results.
We have experience and well-established processes for conducting local literature screenings. We can support you in the set-up and conduct, including the identification of relevant local databases and journals, and translation of articles, if needed.
For Marketing Authorization Holders (MAHs) with active substances included in the EMA’s Medical Literature Monitoring (MLM) list, we perform EudraVigilance checks using the ICSR Export module based on the frequency contracted. In addition, we provide local literature searches in relevant local scientific and medical journals in countries where your product is marketed and where this is legally required.
News & Insights
May 25, 2026
Rethinking the Role of the Medical Information Contact Center: An Untapped Resou...
Explore how Medical Information contact centers can enhance medical writing by leveraging their expertise and adaptability in response to evolving demands.
May 19, 2026
Rethinking Biometrics Resourcing in Modern Clinical Trials
Explore how the Biometrics Functional Service Provider model transforms clinical trials, enhancing data integrity, speed, and long-term performance in a complex landscape.
May 27, 2026
ProPharma Appoints Adrian Pencak as Chief Commercial Officer
ProPharma announces Adrian Pencak as Chief Commercial Officer, bringing 25 years of leadership experience to enhance global commercial capabilities and client partnerships.
January 27, 2026
ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero T...
ProPharma’s greenhouse gas reduction targets are validated by SBTi, aligning with the Net-Zero Standard and a commitment to reach net-zero by 2050.
January 31, 2025
ProPharma Recognized for AI Excellence at ECCCSA
ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.
October 9, 2024
ProPharma Receives 2024 CPHI Regulatory and Compliance Award
ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.
May 20, 2026
Keeping Research Moving Under Pressure: Delivering Data Integrity at Speed - Pro...
When patient enrollment rapidly exceeds expectations, clinical trials can face significant operational strain, putting data integrity, timelines, and critical sponsor decisions at risk. A mid-size...
May 20, 2026
From Clinical Hold to Approval: Overcoming CMC Challenges to Achieve BLA Approva...
A critical CMC change during Phase 3 development led to a partial clinical hold, putting timelines, regulatory alignment, and commercial readiness at risk. In this case study, learn how we partnered...
May 15, 2026
Response to Regulatory Request with Subsequent Full Signal Assessment - ProPharm...
Responding to urgent regulatory safety requests requires balancing speed, scientific rigor, and global compliance. When concerns emerged regarding a potential neurotoxicity signal, the client needed...
June 2, 2026
Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution
A compliant and efficient EU–UK GMP–GDP supply chain requires a clear understanding of roles, responsibilities, and operational integration across importation, certification, and distribution...
April 23, 2026
Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market
As cell and gene therapies transition from clinical development to commercialization, organizations face evolving regulatory expectations, expanded CMC requirements, and increased MAH...
April 9, 2026
EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification
As European Medicines Agency Policy 0070 enters its expanded Step 2 phase, sponsors face increased document volumes, heightened transparency obligations, and greater scrutiny of anonymization and CCI...
News & Insights
May 20, 2026
Keeping Research Moving Under Pressure: Delivering Data Integrity at Speed - Pro...
When patient enrollment rapidly exceeds expectations, clinical trials can face significant operational strain, putting data integrity, timelines, and critical sponsor decisions at risk. A mid-size...
May 20, 2026
From Clinical Hold to Approval: Overcoming CMC Challenges to Achieve BLA Approva...
A critical CMC change during Phase 3 development led to a partial clinical hold, putting timelines, regulatory alignment, and commercial readiness at risk. In this case study, learn how we partnered...
May 15, 2026
Response to Regulatory Request with Subsequent Full Signal Assessment - ProPharm...
Responding to urgent regulatory safety requests requires balancing speed, scientific rigor, and global compliance. When concerns emerged regarding a potential neurotoxicity signal, the client needed...
April 9, 2026
EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification
As European Medicines Agency Policy 0070 enters its expanded Step 2 phase, sponsors face increased document volumes, heightened transparency obligations, and greater scrutiny of anonymization and CCI...